BlinkLab (ASX:BB1) completed testing of the first patient in its digital diagnostic trial for autism at PriMED Clinical Research in Ohio, according to a Wednesday filing with the Australian bourse.
The study aims to validate the BlinkLab Dx1 neurological test as a diagnostic aid for clinicians in early assessment of developmental disorders, the filing said.
PriMED, along with North Shore Pediatric Therapy in Chicago, will participate in the initial study with 100 participants, with data set to be released in the third quarter of the year, per the filing.
Shares rose 7% in afternoon trade Wednesday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。